Mirador Capital Partners LP Celldex Therapeutics, Inc. Transaction History
Mirador Capital Partners LP
- $529 Million
- Q4 2024
A detailed history of Mirador Capital Partners LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Mirador Capital Partners LP holds 119,492 shares of CLDX stock, worth $2.84 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
119,492
Previous 116,147
2.88%
Holding current value
$2.84 Million
Previous $3.95 Million
23.47%
% of portfolio
0.57%
Previous 0.72%
Shares
20 transactions
Others Institutions Holding CLDX
# of Institutions
203Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$220 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$112 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$92 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$82.2 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$79.2 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.11B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...